Recombinant thrombomodulin protects against LPS-induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx

Kodai Suzuki¹ | Hideshi Okada¹ | Genzou Takemura² | Chihiro Takada¹ | Hiroyuki Tomita³ | Hirohisa Yano¹ | Isamu Muraki¹ | Ryogen Zaikokuji¹ | Ayumi Kuroda¹ | Hirotsugu Fukuda¹ | Ayane Nishio¹ | Shigeo Takashima⁴ | Akio Suzuki⁵ | Nagisa Miyazaki² | Tetsuya Fukuta¹ | Noriaki Yamada¹ | Takatomo Watanabe⁶ | Tomoaki Doi¹ | Takahiro Yoshida¹ | Keisuke Kumada¹ | Hiroaki Ushikoshi¹ | Shozo Yoshida¹ | Shinji Ogura¹

¹Department of Emergency and Disaster Medicine, Gifu University Graduate School of Medicine, Gifu, Japan
²Department of Internal Medicine, Asahi University School of Dentistry, Mizuho, Japan
³Department of Tumour Pathology, Gifu University Graduate School of Medicine, Gifu, Japan
⁴Division of Genomics Research, Life Science Research Center, Gifu University, Gifu, Japan
⁵Department of Pharmacy, Gifu University Hospital, Gifu, Japan
⁶Division of Clinical Laboratory, Gifu University Hospital, Gifu, Japan

Background and Purpose: Disruption of the endothelial glycocalyx is causally related to microvascular endothelial dysfunction, a characteristic of sepsis-induced acute respiratory distress syndrome (ARDS). Recombinant human thrombomodulin (rhTM) attenuates vascular endothelial injuries, but the underlying mechanism remains elusive. Here, we investigated the structural basis and molecular mechanisms of rhTM effects on vascular endothelial injury in a model of sepsis.

Experimental Approach: LPS (20 mg kg⁻¹) was intraperitoneally injected into 10-week-old male C57BL6 mice, and saline or rhTM was intraperitoneally injected 3 and 24 h after LPS injection. Using serum and/or lung tissue, histological, ultrastructural, and microarray analyses were performed.

Key Results: Survival rate of rhTM-treated mice was significantly higher than that of control mice 48 h after LPS injection. Serum concentrations of IL-6 and high-mobility group box 1 were lower in the rhTM-treated group than in the control. Injury to the endothelial glycocalyx in pulmonary capillaries was attenuated by rhTM treatment. Gene set enrichment analysis revealed up-regulation of gene sets corresponding to cell proliferation/differentiation and anti-inflammation, such as the TGF-β pathway, and negative regulation of IL-6, upon rhTM treatment. Gene expression of heparan sulfate 6-O-sulfotransferase 1 and endothelial cell-specific molecule 1 (components of the endothelial glycocalyx) was significantly preserved by rhTM treatment, and their protein expression levels were maintained in endothelial cells.
1 | INTRODUCTION

Acute respiratory distress syndrome (ARDS), a clinical phenotype of sepsis, is characterised by a serious inflammatory development comprising neutrophil integration and pro-inflammatory cytokine production, thereby causing injuries to the alveolar–capillary integrity with high-permeability and non-hydrostatic pulmonary oedema (Shao, Tang, Liu, & Zhu, 2016). Under normal conditions, the vascular endothelial glycocalyx covers the surface of endothelial cells and plays a key role in microvascular and endothelial physiology (Chelazzi, Villa, Mancinelli, De Gaudio, & Adembri, 2015). The glycocalyx is an important determinant of vascular permeability (Henry & Duling, 1999; Vink & Duling, 2000). It also regulates neutrophil adhesion and lung injury during sepsis-induced ARDS (Schmidt et al., 2012), and its disruption by LPS is causally related to microvascular endothelial dys-function (Inagawa et al., 2018).

Thrombomodulin, which exists on the surface of endothelial cells and contributes to the maintenance of vascular homeostasis (Esmon, 2005), demonstrates an anti-inflammatory effect by binding to high-mobility group box 1 (HMGB1), a nuclear architectural chromatin-binding protein with roles in DNA organisation and transcription regulation (Kadono et al., 2017). Both DNA organisation and transcription regulation play a crucial role in ARDS progression by promoting lung injury (Abeyama et al., 2005; Ito et al., 2008; Ito & Maruyama, 2011). Soluble recombinant human thrombomodulin (rhTM), consisting of all the extracellular domains of thrombomodulin, has been used to treat patients with disseminated intravascular coagulation (DIC) (Kadono et al., 2017). rhTM binds to thrombin to inhibit its procoagulant activity, promotes protein C activation (Kearon et al., 2005; Khorchidi et al., 2002; Tawara, Sakai, & Matsuzaki, 2016), and reduces the secretion of inflammatory cytokines, including IL-6 and TNF-α, under septic conditions (Takahashi et al., 2016).

However, to our knowledge, no study has yet investigated whether rhTM attenuates pulmonary endothelial glycocalyx injuries under endotoxemic conditions. Therefore, this study aimed to evaluate the condition of the pulmonary endothelial glycocalyx after LPS administration in rhTM-treated mice.

2 | METHODS

2.1 | In vivo animal studies

All animal care and experimental procedures in this study conformed to the Guide for the Care and Use of Laboratory Animals (NIH Publication, 8th Edition, 2011) and were approved by the Institutional Animal Research Committee of Gifu University (30-190, Gifu, Japan).

Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the recommendations made by the British Journal of Pharmacology. All efforts were made to minimise animals’ suffering and reduce the number of animals used. Ten-week-old male C57BL6 mice (RRID: MGI:5657202; Chubu Kagaku Shizai, Nagoya, Japan) were housed in a colony room maintained at 25°C with a 12:12 h light/dark cycle. For all experiments, animals had free access to powdered mouse chow (CE-2 Rodent Diet, Nihon CLEA Ltd., 3.40 kcal·g−1; 25.1% protein, 4.51% fat, and 49.7% carbohydrate) before and after 16-h starvation, and tap water, unless otherwise specified. Power analyses (α = 0.05, 1 − β = 0.95) using an estimated effect size of 1 (based on previous studies, Suzuki et al., 2019) indicated a minimum necessary sample size of five or six animals per treatment group for the experiments described below.

Following 16-h starvation, mice were injected i.p. with LPS (20 mg·kg−1; Millipore Sigma, Burlington, MA) and, in some assays, with recombinant human thrombomodulin (rHTM, 30 mg·kg−1; Asahi Kasei Pharma Corporation, Tokyo, Japan) at 3 and 24 h after LPS injection once per day, similar to the clinical use of rhTM in humans. In sham-operated mice, PBS was injected instead of LPS. Also as a control, PBS was administered instead of rhTM in the same manner. Mice were distributed to each group in a blinded manner. Survival rate was determined every 6 h after LPS administration. Perfusion fixation and blood sampling from the ophthalmic artery were performed under

Conclusion and Implications: Our findings show that rhTM treatment affected inflammation, cell proliferation/differentiation, and glycocalyx synthesis in serum and lung tissue, subsequently attenuating ARDS caused by endothelial injury.

What is already known

- The endothelial glycocalyx is injured during endotoxaemia and exacerbates the acute respiratory distress syndrome.

What this study adds

- Recombinant human thrombomodulin protects against endothelial injury by accelerating endothelial glycocalyx synthesis.

What is the clinical significance

- Recombinant human thrombomodulin could exert beneficial effects against acute respiratory distress syndrome.
anaesthesia (using a mixture of medetomidine hydrochloride 0.3 mg kg\(^{-1}\), midazolam 4 mg kg\(^{-1}\), and butorphanol tartrate 5 mg kg\(^{-1}\), given i.p.). The anaesthesia was deemed sufficient if the corneal and hind-paw withdrawal reflexes were absent. Before lung specimens were obtained, the mice were killed by exsanguination from the ophthalmic artery until the righting reflex was lost.

2.2 | Serum preparation and ELISA

Blood samples were collected from six mice, from the buccal artery, which branches off the maxillary artery, allowed to clot at 25°C for 2 h, and centrifuged (2,000 x g, 4°C for 20 min). The supernatant (serum) was then collected. Serum IL-6 was measured using ELISA quantitation kits for mouse IL-6 (Cat No. M6000B, R&D Systems). HMGB1 was measured using ELISA quantitation kits for mouse HMGB-1 by SRL (Hachioji, Tokyo, Japan).

2.3 | Histopathological examination

Whole right lobes from the lungs of six individual mice 48 h after LPS administration were fixed with PBS containing 10% formalin and embedded in paraffin. Paraffin sections (4 μm) were then deparaffinised and rehydrated. Finally, slides were counterstained with haematoxylin and eosin, and the coverslipped lung sections were scored as follows for pulmonary oedema: 1 = absent; 2 = detectable seroproteinaceous fluid in one to a few alveoli; or 3 = seroproteinaceous fluid-filled alveoli in a multifocal to coalescing pattern in the lungs. Neutrophilic infiltration was scored: 1 = absent or rare solitary neutrophils; 2 = detectable extravasated neutrophils observed as small loose cellular aggregates in one or a few airways and/or alveoli; 3 = detectable extravasated neutrophils observed as loose to compact cellular aggregates in multiple to coalescing airway and/or alveoli with some effacement of lung architecture; 4 = detectable extravasated neutrophils observed as compact cellular aggregates effacing most adjacent lung architecture (Langlois et al., 2010). These experiments were performed in a blinded manner to avoid bias.

2.4 | Western blotting

Total protein concentration in tissue lysates was measured using bicinchoninic acid protein assays, and 10 μg of protein was separated by 10% SDS-PAGE and transferred onto nitrocellulose membranes (Millipore Sigma, Billerica, MA). Membranes were probed with antibodies against syndecan-1 (ab34164; Abcam, Cambridge, UK) or α-tubulin (sc-5546; Santa Cruz Biotechnology, Dallas, TX), and immunoreactive bands were visualised using enhanced chemiluminescence (GE Healthcare UK). Signal intensities were quantified (as arbitrary units) using ImageJ. Western blotting was performed on five independent samples from individual mice from each group.

2.5 | Scoring of lectin-staining intensity

For quantitative analysis of glyocalyx injury, scoring of wheat germ agglutinin (WGA, B-1025-5; Vector Laboratories, Burlingame, CA, USA) staining intensity was performed using a fluorescence microscope (BZ-X810. Keyence, Osaka, Japan) and ImageJ software. After deparaffinisation, sections (4 μm) were cut and incubated with WGA biotin conjugate (BK-1000, Vector Laboratories, Burlingame, CA) at 4°C overnight. After washing with PBS three times, the sections were incubated with DyLight 594 Streptavidin (SA-5594, Vector Laboratories, Burlingame, CA) at 1:200 dilution in PBS at room temperature for 1 h. After washing with PBS twice, the sections were covered by coverslips. The intensity of WGA expression was scored manually in 10 high-power fields per sample (n = 6 per sample), in the focal plane.

2.6 | Immunohistochemistry

After deparaffinisation, the sections (4 μm) were cut and incubated with primary antibodies against Ki-67 (ab16667; Abcam, Cambridge, UK), heparan sulfate 6-O-sulfotransferase 1 (HS6ST1, bs-10701R; Bioss Antibodies, Woburn, MA, USA), endothelial cell-specific molecule 1 (ESM 1; ab103590; Abcam, Cambridge, UK), and the endothelial cell marker CD31 (M0823; Dako, Santa Clara, CA, USA). The target proteins were visualised using the VECTASTAIN Elite ABC system (Vector Laboratories) or the secondary antibodies (Alexa Fluor 488 and 568, Invitrogen) and Hoechst nuclear stain. The immunorelated procedures used comply with the recommendations made by the British Journal of Pharmacology.

2.7 | Electron microscopy

Electron microscopic analysis of the endothelial glycocalyx was performed as described previously (Inagawa et al., 2018; Okada et al., 2017). Briefly, mice were anaesthetised and then perfused with a solution composed of 2% glutaraldehyde, 2% sucrose, 0.1-M sodium cacodylate buffer (pH 7.3), and 2% lanthanum nitrate, at a steady flow rate of 1 ml min\(^{-1}\), through a cannula placed in the left ventricle. After mice were killed, lung samples were fixed in a solution without glutaraldehyde and washed thereafter in alkaline (0.03-M NaOH) 2% sucrose solution. The freeze-fracture method was used to prepare samples for scanning electron microscopy (S-4800, Hitachi, Tokyo, Japan), but the method for transmission electron microscopy included embedding the specimens in epoxy resin followed by generation of ultrathin (90-nm) sections that were stained with uranyl acetate and lead citrate and subjected to transmission electron microscopy analysis (HT-7700, Hitachi). To prepare samples for conventional electron microscopy, 2.5% glutaraldehyde in 0.1-M phosphate buffer (pH 7.4) without lanthanum nitrate was used as the fixative.
2.8 | Microarray analysis

For microarray analysis, lung tissues were obtained from both saline- or rhTM-treated mice 30 h after LPS administration (n = 3 each). Total RNA was extracted using a simplyRNA Tissue Kit (Promega, Fitchburg, WI, USA) on a Maxwell RSC instrument. Gene expression analysis of the RNA samples was performed using an Agilent Expression Array (SurePrint G3 Mouse GE 8 x 60K Microarray). The obtained data were analysed and visualised with MeV MultiExperiment Viewer and DAVID. Differentially expressed genes between the rTM-treated and control saline groups were identified based on the fold change of at least 2 (up-regulated) or less than 0.5 (down-regulated) and a P value of less than 0.01. Further, gene set enrichment analysis (GSEA) was used to analyse pathway enrichment (http://software.broadinstitute.org/gsea/index.jsp). All microarray data were deposited in the Gene Expression Omnibus (GEO) under Dataset Accession No. GSE130362 (http://www.ncbi.nlm.nih.gov/geo/).

2.10 | Data and statistical analysis

Data are presented as means ± SEM. Student’s two-tailed t test was used for comparing the two groups, and survival data were analysed using the log-rank test; P < 0.05 was considered significant. All calculations were performed using GraphPad Prism (Ver. 7.02; La Jolla, CA). The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology.

2.11 | Materials

Recombinant human thrombomodulin was provided by Asahi Kasei Pharma Corporation.

2.12 | Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).

3 | RESULTS

3.1 | Treatment with rhTM improved survival after LPS injection

To produce an experimental model of endotoxaemia, LPS (20 mg kg⁻¹) was administered i.p. to 10-week-old C57BL6 male mice. The survival rate at 30 h after LPS injection was 65% (52/80) in the control group mice, after which it significantly decreased to 28% (22/80) by 36 h after LPS administration. Alternatively, at 48 h after LPS administration, the survival rate of rhTM-treated mice was significantly improved over that of control mice (Figure 1a).

In control mice receiving LPS only, IL-6 levels were significantly raised at 6 h after LPS injection and peaked at 12 h after injection. Thereafter, IL-6 levels returned to baseline within 48 h after LPS injection (Figure 1b). In rhTM-treated mice, IL-6 concentrations were significantly decreased at 6 and 12 h after LPS administration compared with those in control mice. Moreover, serum HMGB1 levels were decreased in rhTM-treated mice compared with that in untreated mice 48 h after LPS administration (Figure 1c).

To assess pulmonary injury 48 h after LPS injection, we used the previously reported clinical scoring system (Figure 1d-g) (Langlois et al., 2010; Meyerholz et al., 2008). LPS-injected mice showed increased levels of pulmonary oedema and neutrophil infiltration compared with sham mice. Conversely, rhTM treatment resulted in a significant decrease in both pulmonary oedema and neutrophil infiltration compared with those in saline-injected mice after LPS administration. These data suggest the attenuation of pulmonary injury by rhTM treatment after LPS administration.

3.2 | Pulmonary endothelial glycocalyx injury was attenuated in rhTM-treated mice

Syndecan-1, a component of the glycocalyx, was found to be degraded after LPS administration. However, syndecan-1 degradation was markedly attenuated in rhTM-treated mice compared with that in
saline-treated mice (Figure 2a,b). To quantitatively assess endothelial glycocalyx injury, we performed intensity measurements using WGA staining, which enabled visualisation of endothelial glycocalyx (Kataoka et al., 2016).

WGA intensity was reduced in saline-injected mice after LPS administration compared with that in sham mice (Figure 2c,d). After LPS injection, WGA intensity was increased in rhTM-treated mice compared with that in saline-treated mice. These results together suggest that endothelial glycocalyx injury in lung capillaries was attenuated by rhTM treatment.

### 3.3 rhTM maintained endothelial glycocalyx structure under endotoxaemic conditions

The ultrastructure of the endothelium and endothelial glycocalyx was analysed using electron microscopy. Conventional scanning electron microscopy results showed the pulmonary capillaries to be of the continuous type, characterised by the presence of an uninterrupted endothelium and a continuous basal lamina, in sham mice (Figure 3a,d). After LPS administration, granulocytes were frequently observed in the pulmonary capillaries, and the inner surface of the vascular endothelium became rough, probably owing to vasculitis by LPS-induced endotoxaemia (Figure 3b,e). Conversely, rhTM treatment attenuated these effects (Figure 3c,f). To visualise the endothelial glycocalyx, lanthanum nitrate staining was performed. In sham mice, the endothelial glycocalyx was observed to form a continuous structure and cover the inner surface of the vascular endothelium (Figure 3g). After LPS administration, the endothelial glycocalyx was degraded, and its continuous structure was broken in the untreated mice, whereas the continuous structure of endothelial glycocalyx was retained in the rhTM-treated mice (Figure 3h,i).

Conventional transmission electron microscopy revealed a smooth inner surface of the vascular endothelium and thin endothelial wall in...
sham mice (Figure 4a,d). However, after LPS injection, the inner surface of the vascular endothelium became rough, and the endothelial wall became oedematous (Figure 4b,e). Conversely, rhTM treatment attenuated endothelial oedema after LPS administration (Figure 4c,f).

Lanthanum nitrate-stained transmission electron microscopy revealed that the endothelial glyocalyx indeed forms a continuous structure and covers the inner surface of the vascular endothelium (Figure 4g,j). After LPS injection, the endothelial glyocalyx was peeled...
away, thereby breaking the continuous structure in untreated mice. Conversely, in the rhTM-treated group, the continuous structure of the glyocalyx was maintained, and endothelial glyocalyx injury was attenuated (Figure 4h,i,k,l). These results indicate that rhTM treatment attenuated endothelial glyocalyx injury under endotoxaemia.

3.4 | GSEA following rhTM treatment in the lungs

Because rhTM treatment was found to significantly improve survival rate following LPS injection, we next sought to comprehensively determine which genes were affected by rhTM treatment. To this end, GSEA was performed in the control saline- and rhTM-treated groups. The expression of HS6ST1 and ESM 1 (components of the endothelial glyocalyx) was significantly increased following rhTM treatment, with their expression shown to be the 4th and 20th highest among all 13,337 genes respectively (Figure 5a). To further confirm the GSEA results, qRT-PCR was performed for HS6ST1 and ESM in the saline- and rhTM-treated groups. Results found that the expression of HS6ST1 and ESM 1 in rhTM-treated mice was significantly increased compared with that in the control mice. These results were consistent with those obtained via microarray analysis (Figure S1). Moreover, following Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of GSEA, gene sets associated with placental blood vessel development (Figure 5b), negative regulation of IL-6 (Figure 5c), and the TGF-β and JAK–STAT signalling pathway (Figure 5d,e) were significantly up-regulated in the rhTM-treated group compared with those in the control group (P < 0.01). Conversely, the expression of genes associated with glycosaminoglycan degradation was not found to differ significantly between the rhTM-treated and control mice (Figure S2). Additionally, the qRT-PCR results revealed no significant differences in the expression of HPSE (heparinase), an enzyme that degrades polymeric heparan sulfate molecules, between rhTM-treated and saline-injected mice (Figure S3). Together, these results suggest that rhTM treatment may functionally affect anti-inflammatory, cell proliferation or differentiation and glyocalyx synthesis pathways.
3.5 | Ki67, HS6ST1, and ESM 1 expression in pulmonary capillaries

Next, to determine the cell proliferation and differentiation capacity, as well as the cellular distribution of HS6ST1 and ESM 1 proteins, immunohistochemical analysis was performed. Specifically, Ki67 expression, a cell proliferation and differentiation marker, was found to be increased in rhTM-treated mice, compared with the sham and saline-treated mice (Figure 6a,b). Moreover, HS6ST1 expression was observed in several cell types including inflammatory and endothelial cells. However, its expression in endothelial cells was particularly increased in rhTM-treated mice compared with sham and saline-treated mice (Figure 6c,d). To provide further confirmation, double immunostaining for HS6ST1 and CD31, an endothelial cell marker, was performed and HS6ST1 and CD31 were found to be co-localised in rhTM-treated mice (Figure 6e).

Further, ESM 1 was also expressed in endothelial cells of all experimental groups and in several cell types including inflammatory cells. However, the highest number of ESM 1-positive endothelial cells was observed in rhTM-treated mice (Figure 7a,b); meanwhile, both ESM 1 and CD31 were found to be co-localised in lungs of mice treated with rhTM (Figure 7c). Taken together, these results suggest that rhTM treatment may increase cell proliferation and differentiation and that glycocalyx synthesis may be promoted by HS6ST1 and ESM 1.

4 | DISCUSSION

This study revealed that rhTM treatment attenuated pulmonary endothelial glycocalyx injuries in mice after LPS administration as compared with that in saline-treated WT mice. The endothelial glycocalyx covers the surface of healthy vascular endothelial cells and plays an important role in vascular homeostasis (Becker, Chappell, & Jacob, 2010; Chelazzi et al., 2015; Luft, 1966; Okada et al., 2017; Rehm et al., 2004; Reitsma, Slaaf, Vink, van Zandvoort, & Oude Egbrink, 2007; Woodcock & Woodcock, 2012). Previously, it was reported that intact glycocalyx is protective against endothelial disorders (Frati-Munari, 2013; Gunst et al., 2013). Although this has been applied in specific clinical therapeutic strategies to treat sepsis through endothelial glycocalyx protection (Liu et al., 2018; Wang et al., 2016), these beneficial effects remain controversial and the associated mechanisms had yet to be characterised. Our findings suggest that rhTM may be involved in this glycocalyx protective effect as well as in glycocalyx synthesis.

4.1 | rhTM accelerates glycocalyx synthesis

Endothelial glycocalyx is synthesised by and covers the surface of endothelial cells in vitro as shown by experiments using HUVEC (Martin, Liberati, & Diebel, 2017). Therefore, the restoration and
FIGURE 6  Immunohistochemical analysis of Ki67 and heparan sulfate 6-O-sulfotransferase 1 (HS6ST1). (a) Immunohistochemical analysis of Ki67 in the lungs of sham mice and saline-injected and recombinant human thrombomodulin (rhTM)-treated mice after LPS administration. Arrows indicate Ki67-positive cells. (b) Graph showing Ki67-positive cell numbers (n = 6 each). *P < .05, significantly different from sham mice. (c) Immunohistochemical analysis of HS6ST1 in the lungs of sham mice and saline-injected and rhTM-treated mice after LPS administration. Arrows indicate HS6ST1-positive endothelial cells. (d) Graph showing HS6ST1-positive cell numbers (n = 6 each). *P < .05, significantly different from sham mice. (e) Double immunofluorescence analysis of HS6ST1 and CD31. The magnified image is the expanded view of the white-boxed area in the merged image. HPF, high-power field.

FIGURE 7  Immunohistochemical analysis of endothelial cell-specific molecule 1 (ESM 1). (a) Immunohistochemical analysis of ESM 1 in the lungs of sham mice and saline-injected and recombinant human thrombomodulin (rhTM)-treated mice after LPS administration. Black arrows indicate ESM 1-positive endothelial cells. Red arrows indicate ESM 1-positive inflammatory cells. (b) Graph showing ESM 1-positive cell numbers (n = 6 each). *P < .05, significantly different from sham mice. †P < .05, significantly different from saline+LPS group. (c) Double immunofluorescence analysis of ESM 1 and CD31. The magnified image is the expanded view of the white-boxed area in the merged image. HPF, high-power field.
proliferation of endothelial cells are assumed to be closely related to endothelial glycocalyx synthesis, under septic conditions. The current study revealed accelerated endothelial cell proliferation in rhTM-treated mice, as supported by GO analysis, which suggested the gene set of TGF-β signalling pathway and JAK–STAT pathway to be up-regulated in rhTM-treated mice. Because the TGF-β signalling pathway and JAK–STAT pathway contribute to cell proliferation, survival, and differentiation, these pathways are expected to be related to survival and restoration of endothelial cells under septic conditions. However, growth factors such as FGF-10, which occupy roles in cell tissue morphogenesis especially lung development, were recently reported to require heparin sulfate for their function (Chan, Price, & Pratt, 2017; Knelson, Nee, & Blobe, 2014). In addition, FGF signalling has been reported to mediate pulmonary endothelial glycocalyx reconstitution (Yang et al., 2017).

We found that rhTM treatment up-regulated the gene set associated with placental blood vessel development, including the heparan sulfate 6-O-sulfotransferase 1 (HS6ST1) gene. This gene is a member of the heparan sulfate biosynthetic enzyme family (Habuchi, Habuchi, & Kimata, 2004) and, as such, is essential for heparan sulfate synthesis, one of the primary components of the endothelial glycocalyx (Reitsma et al., 2007). As HS6ST1 deficiency is lethal in mice primarily during the later embryonic stages, resulting in abnormal angiogenesis in the labyrinthine zone of the placenta along with aberrant lung morphology similar to that observed in pulmonary emphysema (Habuchi et al., 2007), HS6ST1 is considered to be essential for angiogenesis also in the pulmonary circulation. Furthermore, cell surface heparan sulfate proteoglycans interact with a myriad of growth factors, receptors and extracellular matrix proteins, resulting in regulation of many receptor–ligand interactions (Habuchi et al., 2004). Thus, heparan sulfate has important functions in a variety of developmental, morphogenetic and pathogenic processes (Habuchi et al., 2007). Heparan sulfate biosynthetic enzymes play important roles in producing numerous distinct heparan sulfate fine structures that perform multiple biological activities. Heparan sulfate is also a component of the endothelial glycocalyx and has been recently reported to be associated with endothelial glycocalyx regeneration (Mensah et al., 2017).

Our current study also indicated that ESM 1 expression was increased in rhTM-treated mice. ESM 1 is a dermatan sulfate proteoglycan that is principally expressed in pulmonary microcirculation as one of the glycocalyx components (Bechard et al., 2000; Lassalle et al., 1996; Orbeogo et al., 2017; Zhang et al., 2012). ESM 1 expression increases in the presence of pro-angiogenic growth factors, such as FGF-2 or VEGF (Aitkenhead et al., 2002; Rennel et al., 2007). It also contributes to the pathophysiology of ARDS (Bull, Clark, McFann, Moss, National Institutes of Health/National Heart, & Blood Institute, 2010; Cross & Matthy, 2011; Orbeogo et al., 2017; Tang et al., 2014; Thille et al., 2013). Therefore, not only heparan sulfate and dermatan sulfate proteoglycan but also several glycosaminoglycans such as hyaluronic acid and sialic acid are considered to be endothelial glycocalyx components. Further, the up-regulation of HS6ST1 and ESM 1, upon rhTM treatment, is suggested to contribute to endothelial glycocalyx biosynthesis. However, rhTM does not accelerate glycosaminoglycan degradation.

### 4.2 rhTM inhibits glycocalyx injuries through its anti-inflammatory effects

The pulmonary endothelial glycocalyx becomes injured by inflammatory conditions such as sepsis (Inagawa et al., 2018). Therefore, inhibition of inflammation may protect the endothelial glycocalyx structure (Fukuta et al., 2019; Suzuki et al., 2019). Moreover, excessive secretion of IL-6 causes cellular injury during sepsis (Tanaka, Narazaki, & Kishimoto, 2014). The present study revealed that serum IL-6 concentration was reduced by rhTM treatment, consistent with the gene set analysis results of negative regulation of IL-6 production by rhTM.

Although the beneficial effects of rhTM, used in clinical conditions, remains controversial (Vincent et al., 2019; Yamakawa et al., 2016; Yoshihiro et al., 2019), rhTM treatment is known to decrease administration of albumin in patients with severe sepsis-induced DIC (Hagiwara, Tanaka, Uemura, Matsuda, & Kimura, 2016). Hence, this phenomenon may be involved in decreasing vascular permeability via glycocalyx protection induced by rhTM treatment.

Moreover, the current study showed that rhTM can inhibit serum HMGB1 concentration during endotoxaemia. Because HMGB1 induces the secretion of IL-1β, TNF-α, and IL-6 from several types of inflammatory cells, including neutrophils and macrophages, it plays an important role in initiating and maintaining the amplification of the inflammatory cascade (Fu et al., 2016; Takahashi et al., 2016), consistent with previous reports that suggested that the N-terminus of thrombomodulin binds to and decomposes HMGB1, subsequently exerting an anti-inflammatory effect (Abeyama et al., 2005; Ito et al., 2008; Ito & Maruyama, 2011).

### 4.3 Study limitations

Sepsis is an extremely complex condition in humans compared with simple endotoxaemia in an experimental model. Because our focus in this study was to investigate the direct relationship between endothelial glycocalyx injury and septic vasculitis, we used an endotoxaemia model that does not reflect certain typical septic conditions such as bacterial infection. Thus this would represent a limitation of our current study. In this study, rhTM was administered at a high dose of 30 mg·kg\(^{-1}\), because rhTM used was the human, rather than murine, recombinant form. In addition, the route of administration was i.p. and not i.v., as would be typical in a clinical setting.

Although it was shown here that rhTM up-regulates genes involved in glycocalyx synthesis in the endothelium, which translates to improved glycocalyx coverage and overall survival in LPS-induced ARDS, further confirmatory studies, including the use of knockout mice, are necessary to fully elucidate the precise mechanisms that allow rhTM to promote endothelial glycocalyx synthesis under conditions of sepsis.
In conclusion, our data has shown that rhTM treatment protected the endothelial glyocalyx from endotoxaemia-induced lung injury in mice. This mechanism may reduce the damage associated with inflammation and acceleration of the biosynthesis of the glyocalyx itself. As rhTM is currently used in clinical applications, it may be considered as a novel strategy against septic vasculitis, through its ability to protect the endothelial glyocalyx.

ACKNOWLEDGEMENTS
We thank Yuki Wakida, Yasuko Nogaki, and Shoko Kumazaki for technical assistance. This study was supported in part by Grants-in-Aid for Scientific Research (Japan Society for the Promotion of Science: 19H03756, 19K18347, 19K09410, 18K08914, 18K08884, 18K16511, 17K11569, 16H05497, 16K09509, 16K20381, and 15K10973) from the Ministry of Education, Science, and Culture of Japan. Financial support for this study was also provided in part by Asahi Kasei Pharma Corporation, Tokyo, Japan.

CONFLICT OF INTEREST
None.

AUTHOR CONTRIBUTIONS
K.S. and H.O. wrote the manuscript. C.T. prepared the samples for transmission electron microscopy imaging. G.T., C.T., and N.M. performed the transmission electron microscopy imaging. K.S., C.T., H.F., and A.N. made the sample for scanning electron microscopy imaging. K.S., H.O., I.M., A.K., and H.F. performed the scanning electron microscopy imaging. K.S., C.T., H.Y., A.K., A.N., T.W., and S.Y. performed the animal studies. A.S. and T.W. performed the ELISA experiment. R.Z., T.D., and K.K. performed the immunohistochemistry. H.T., H.Y., T.F., and H.U. assessed the histological score and cell counts. H.O. and S.T. performed the microarray analysis. H.O., S.T., and H.T. analysed the gene set enrichment analysis. G.T. and S.O. supervised the animal studies. H.O. and G.T. revised and edited the manuscript. All authors have read and approved the final manuscript.

DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the *BJP* guidelines for *Design and Analysis, Immunoblotting and Immunocytochemistry, and Animal Experimentation* and as recommended by funding agencies, publishers, and other organisations engaged with supporting research.

DATA AVAILABILITY STATEMENT
The microarray data reported in this paper have been deposited in the Gene Expression Omnibus database under the Accession Number GSE 130362 (http://www.ncbi.nlm.nih.gov/geo/).

REFERENCES
Aitkenhead, M., Wang, S. J., Nakatsu, M. N., Metestas, J., Heard, C., & Hughes, C. C. (2002). Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: Induction of ESM-1, iig-h3, and NcCAM. *Microvascular Research*, 63, 159–171. https://doi.org/10.1006/mvre.2001.2380
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., … CGTP Collaborators. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. *British Journal of Pharmacology*, 176, S297–S396. https://doi.org/10.1111/bph.14752
Bechard, D., Meiginin, V., Scherpereel, A., Oudin, S., Kervoaze, G., Bertheau, P., … Lassalle, P. (2000). Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. *Journal of Vascular Research*, 37, 417–425. https://doi.org/10.1159/000025758
Becker, B. F., Chappell, D., & Jacob, M. (2010). Endothelial glyocalyx and coronary vascular permeability: The fringe benefit. *Basic Research in Cardiology*, 105, 687–701. https://doi.org/10.1007/s00395-010-0118-z
Bull, T. M., Clark, B., McFann, K., Moss, M., & National Institutes of Health/National Heart L, & Blood Institute AN. (2010). Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury. *American Journal of Respiratory and Critical Care Medicine*, 182, 1123–1128. https://doi.org/10.1164/rccm.201002-0250OC
Chan, W. K., Price, D. J., & Pratt, T. (2017). FGF8 morphogen gradients are differentially regulated by heparan sulphotransferases Hs2st and Hs6st1 in the developing brain. *Biology Open*, 6, 1933–1942. https://doi.org/10.1242/bio.028605
Chefazzi, C., Villa, G., Mancinelli, P., De Gaudio, A. R., & Adembri, C. (2015). Glyocalyx and sipsis-induced alterations in vascular permeability. *Critical Care*, 19, 26. https://doi.org/10.1186/s13054-015-0741-z
Constantinescu, S. N., Girardot, M., & Pecquet, C. (2008). Mining for JK–STAT mutations in cancer. *Trends in Biochemical Sciences*, 33, 122–131. https://doi.org/10.1016/j.tibs.2007.12.002
Cross, L. J., & Matthias, M. A. (2011). Biomarkers in acute lung injury: Insights into the pathogenesis of acute lung injury. *Critical Care Clinics*, 27, 355–377. https://doi.org/10.1016/j.ccc.2010.12.005
Esmon, C. T. (2005). The interactions between inflammation and coagulation. *British Journal of Haematology*, 131, 417–430. https://doi.org/10.1111/j.1365-2141.2005.05753.x
Fratì-Munari, A. C. (2013). Medical significance of endothelial glyocalyx. *Archivos de Cardiología de México*, 83, 303–312. https://doi.org/10.1016/j.acmx.2013.04.015
Fu, J., Lin, S. H., Wang, C. J., Li, S. Y., Feng, X. Y., Liu, Q., & Xu, F. (2016). HMGB1 regulates IL-33 expression in acute respiratory distress syndrome. *International Immunopharmacology*, 38, 267–274. https://doi.org/10.1016/j.intimp.2016.06.010
Fukuta, T., Okada, H., Takemura, G., Suzuki, K., Takada, C., Tomita, H., … Ogura, S. (2019). Neutrophil elastase inhibition ameliorates endotoxin-induced myocardial injury accompanying degradation of cardiac capillary glyocalyx. *Shock, Publish Ahead of Print*. https://doi.org/10.1097/ SHK.0000000000001482
Gunst, J., Derese, I., Aertgeerts, A., Ververs, E. J., Wauters, A., Van den Berge, G., & Vanhorebeek, I. (2013). Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness. *Critical Care Medicine*, 41, 182–194. https://doi.org/10.1097/CCM.0b013e3182676657
Haan, C., Kreis, S., Margue, C., & Behmann, I. (2006). Jaks and cytokine receptors—An intimate relationship. *Biochemical Pharmacology*, 72, 1538–1546. https://doi.org/10.1016/j.bcp.2006.04.013

ORCID
Hideshi Okada https://orcid.org/0000-0002-7775-4308
Hiroyuki Tomita https://orcid.org/0000-0002-3291-0274
Schmierer, B., & Hill, C. S. (2007). TGFβ-SMAD signal transduction: Molecular specificity and functional flexibility. Nature Reviews. Molecular Cell Biology, 8, 970–982. https://doi.org/10.1038/nrm2297

Shao, M., Tang, S. T., Liu, B., & Zhu, H. Q. (2016). Rac1 mediates HMGB1-induced hyperpermeability in pulmonary microvascular endothelial cells via MAPK signal transduction. Molecular Medicine Reports, 13, 529–535. https://doi.org/10.3892/mmr.2015.4521

Suzuki, K., Okada, H., Takemura, G., Takada, C., Kuroda, A., Yano, H., ... Ogura, S. (2019). Neutrophil elastase damages the pulmonary endothelial glycocalyx in lipopolysaccharide-induced experimental endotoxemia. The American Journal of Pathology, 189, 1526–1535. https://doi.org/10.1016/j.ajpath.2019.05.002

Takahashi, Y., Matsuhashi, N., Dejima, H., Nakayama, T., Okamura, R., Uehara, H., & Kawamura, M. (2016). Therapeutic potential of recombinant thrombomodulin for lung injury after pneumonectomy via inhibition of highmobility group box 1 in mice. Journal of Trauma and Acute Care Surgery, 81, 868–875. https://doi.org/10.1097/TA.0000000000001208

Tanaka, T., Narazaki, M., & Kishimoto, T. (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology, 6, a016295. https://doi.org/10.1101/cshperspect.a016295

Tawara, S., Sakai, T., & Matsuzaki, O. (2016). Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin. Thrombosis Research, 147, 72–79. https://doi.org/10.1016/j.thromres.2016.09.011

Thille, A. W., Esteban, A., Fernandez-Segoviano, P., Rodriguez, J. M., Aramburu, J. A., Vargas-Erazuriz, P., ... Frutos-Vivar, F. (2013). Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: A prospective cohort study of clinical autopsies. The Lancet Respiratory Medicine, 1, 395–401. https://doi.org/10.1016/S2213-2600(13)70053-5

Vincent, J. L., Francois, B., Zabolotskikh, I., Daga, M. K., Lascarrou, J. B., Kirov, M. Y., ... for the SCARLET Trial Group. (2019). Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial. JAMA, 321, 1993–2002. https://doi.org/10.1001/jama.2019.5358

Vink, H., & Duling, B. R. (2000). Capillary endothelial surface layer selectively reduces plasma solute distribution volume. American Journal of Physiology, Heart and Circulatory Physiology, 278, H285–H289. https://doi.org/10.1152/ajpheart.2000.278.1.H285

Wang, L., Huang, X., Kong, G., Xu, H., Li, J., Hao, D., ... Wang, X. (2016). Ulinastatin attenuates pulmonary endothelial glycocalyx damage and inhibits endothelial heparanase activity in LPS-induced ARDS. Biochemical and Biophysical Research Communications, 478, 669–675. https://doi.org/10.1016/j.bbrc.2016.08.005

Woodcock, T. E., & Woodcock, T. M. (2012). Revised Starling equation and the glycocalyx model of transvascular fluid exchange: An improved paradigm for prescribing intravenous fluid therapy. British Journal of Anaesthesia, 108, 384–394. https://doi.org/10.1093/bja/aeq515

Yamakawa, K., Umemura, Y., Hayakawa, M., Kudo, D., Sanui, M., Takahashi, H., ... Fuji, S. (2016). Benefit profile of anticoagulant therapy in sepsis: A nationwide multicentre registry in Japan. Critical Care, 20, 229. https://doi.org/10.1186/s13054-016-1415-1

Yang, Y., Haeger, S. M., Suffita, M. A., Zhang, F., Dailey, K. L., Colbert, J. F., ... Schmidt, E. P. (2017). Fibroblast growth factor signaling mediates pulmonary endothelial glycocalyx reconstitution. American Journal of Respiratory Cell and Molecular Biology, 56, 727–737. https://doi.org/10.1165/rcmb.2016-0338OC

Yoshiihro, S., Sakuraiya, M., Hayakawa, M., Ono, K., Hirata, A., Takaba, A., ... Hashimoto, Y. (2019). Recombinant human-soluble thrombomodulin contributes to reduced mortality in sepsis patients with severe respiratory failure: A retrospective observational study using a multicenter database. Shock, 51, 174–179. https://doi.org/10.1097/SHK.0000000000001148

Yu, H., Parodi, D., & Jove, R. (2009). STATs in cancer inflammation and immunity: A leading role for STAT3. Nature Reviews. Cancer, 9, 798–809. https://doi.org/10.1038/nrc2734

Zhang, S. M., Zuo, L., Zhou, Q., Gui, S. Y., Shi, R., Wu, Q., ... Wang, Y. (2012). Expression and distribution of endocan in human tissues. Biotechnic & Histochemistry, 87, 172–178. https://doi.org/10.3109/10520295.2011.577754

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Suzuki K, Okada H, Takemura G, et al. Recombinant thrombomodulin protects against LPS-induced acute respiratory distress syndrome via preservation of pulmonary endothelial glycocalyx. Br J Pharmacol. 2020;177:4021–4033. https://doi.org/10.1111/bph.15153